| ALNYLAM PHARMACE.DL-,0001 |
| USA |
| Gesundheit |
| US02043Q1076 / A0CBCK |
| DUL (Frankfurt) / ALNY (NASDAQ) |
| FRA:DUL, ETR:DUL, DUL:GR, NASDAQ:ALNY |
| Nasdaq100 |
| https://www.alnylam.com/ |
|
Alnylam Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing RNA interference (RNAi) therapeutics. This innovative gene silencing technology targets the root causes of diseases at the genetic level, offering po..
>Volltext.. |
| 32650.57 Mio. EUR |
| 32616.87 Mio. EUR |
| 3765.69 Mio. EUR |
| 708.83 Mio. EUR |
| 507.04 Mio. EUR |
| 3.83 EUR |
| 2609.09 Mio. EUR |
| 1502.77 Mio. EUR |
| 626.22 Mio. EUR |
| 2.23 |
| 70.95% |
| - |
| - |
| - |
| - |
| - |
| ALNYLAM |
| 30.07.26 |